— A salute to Jim Jarrett, Harrison County emergency communications pioneer. “When someone dies, it’s like a library burning down,” Shinnston …

OKLAHOMA CITY, Jan. 27, 2025 /PRNewswire/ -- Progentec, a leader in next-gen diagnostics and digital technologies for the management of autoimmune diseases, today announced that the Centers of Medicare and Medicaid Services (CMS) has issued final payment determinations on the PLA codes for Progentec's aiSLE DX FRI and aiSLE DX DAI biomarker tests. Effective January 1, 2025, Medicare claims for the PLA codes for these tests (0446U and 0447U) will be paid at $840.65 when covered.  This development helps establish a route to increased patient access and test adoption. While the aiSLE DX FRI identifies a SLE patient's future risk of a lupus flare, aiSLE DX DAI measures the level of disease activity in these patients.  These tests are made available to ordering physicians through Mayo Clinic Laboratories (https://news.mayocliniclabs.com/rheumatology/).